All In Biotech

Drug Trial Radar · NCT06989840

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TVB-3567 in Healthy Participants With or Without Acne and to Assess the Effect of Food in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Jun 3, 2025

Primary completion

Jan 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Sagimet Biosciences Inc.Industry
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of TVB-3567 administered orally in healthy participants. Part B will be an open-label, 2-way crossover investigation to assess the effect of food on a single dose of TVB-3567 administered orally in healthy participants. Part C will be a randomized, double-blind, placebo-controlled investigation of multiple ascending doses (MAD) to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants. Part D will be an open-label investigation of two doses of TVB-3567 across two cohorts, to assess the safety, tolerability, PK, and PD/biomarkers of TVB-3567 administered orally in healthy participants with moderate to severe acne.

Conditions

  • Acne

Interventions

  • TVB-3567Drug

    Orally administered capsule

  • PlaceboDrug

    Orally administered capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A - Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Baseline to 7 to 8 days after dosing
  2. Part B - Plasma AUC0-t in fasted and fed conditionsTime frame: Baseline to Day 4
  3. Part B - Plasma AUC0-inf in fasted and fed conditionsTime frame: Baseline to Day 4
  4. Part B - Plasma Cmax in fasted and fed conditionsTime frame: Baseline to Day 4
  5. Part B - Incidence of adverse events (AEs) and serious adverse events (SAEs) under fasted and fed conditionsTime frame: Baseline to 7 to 8 days after dosing
  6. Part C - Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Baseline to 13 to 15 days after the last dose
  7. Part D - Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Baseline to 13 to 15 days after the last dose

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Celerion, Inc.

    Tempe, Arizona · Completed

  • Emeritus Research

    Botany, New South Wales, Australia · Recruiting

  • The Skin Hospital

    Darlinghurst, New South Wales, Australia · Not yet recruiting

  • Emeritus Research

    Camberwell, Victoria, Australia · Recruiting

  • Nucleus Network

    Melbourne, Victoria, Australia · Completed

  • Fremantle Dermatology

    Fremantle, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.